WO2011052750A1 - 抗がん剤の感受性判定マーカー - Google Patents
抗がん剤の感受性判定マーカー Download PDFInfo
- Publication number
- WO2011052750A1 WO2011052750A1 PCT/JP2010/069364 JP2010069364W WO2011052750A1 WO 2011052750 A1 WO2011052750 A1 WO 2011052750A1 JP 2010069364 W JP2010069364 W JP 2010069364W WO 2011052750 A1 WO2011052750 A1 WO 2011052750A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anticancer
- sensitivity
- cancer
- anticancer agent
- anticancer drug
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/18—Water
Definitions
- the present invention relates to an anticancer drug sensitivity determination marker used for determining whether or not a cancer of a subject patient has therapeutic reactivity to an anticancer drug, and its application.
- anticancer agents such as alkylating agents, platinum preparations, antimetabolites, anticancer antibiotics, and anticancer plant alkaloids. These anticancer drugs may or may not be effective depending on the type of cancer. However, it is known that some types of cancer that are recognized as effective may or may not be effective depending on the individual patient. Whether or not an anticancer drug shows an effect on such individual patient's cancer is called anticancer drug sensitivity.
- CPT-11 Irinotecan hydrochloride
- CPT-11 is an anticancer agent developed in Japan and having an action mechanism of topoisomerase I inhibition.
- CPT-11 was approved in January 1994 as an effective drug for non-small cell lung cancer, small cell lung cancer, cervical cancer and ovarian cancer, and in July 1995, gastric cancer, colorectal cancer, breast cancer Indications for squamous cell carcinoma and malignant lymphoma are recognized.
- CPT-11 occupies the position of a global standard therapeutic agent as a first-line drug or second-line drug for multi-drug combination therapy particularly in the region of colorectal cancer, and its usefulness has been recognized (Non-patent Documents 1 to 6). .
- Chemotherapy for advanced and metastatic colorectal cancer is centered on key drugs such as CPT-11 and oxaliplatin, which appeared in the 1990s, and fluorouracil (5-FU), which has been a central treatment for colorectal cancer.
- the combined use with the fluorinated pyrimidine preparation dramatically improved clinical outcomes including survival.
- the response rate is still around 50%, and in the current situation, half of the patients who received anticancer drugs at the high risk of serious side effects have not been effective.
- the cancer chemotherapy treatment schedule is long-term, and after determining how many cool treatments have been performed while observing the occurrence of side effects, it is determined whether the effect has been obtained or whether the administration should be continued as is. Until then, it took a long time, expensive medical expenses, and side effects have occurred. Therefore, if there is a means for predicting whether or not an effect can be obtained for each patient before treatment or at an early stage of treatment, the burden on the patient and the occurrence of side effects can be reduced, and medical costs can be reduced.
- CPT-11 itself has antitumor activity, it is activated by carboxyesterase in the body and has an antitumor activity of about 100 to several thousand times stronger than CPT-11 (7-ethyl-10-hydroxycamptothecin (SN-38)). ). It is considered that CPT-11 and SN-38 are present in the body at the same time to exhibit an antitumor effect.
- SN-38 is glucuronidated by UDP-glucuronosyltransferase (UGT) in hepatocytes to become a non-cytotoxic SN-38 glucuronide conjugate (SN-38G), mainly in bile It is excreted and transferred to the intestinal tract, and then excreted in the stool.
- UDP-glucuronosyltransferase UDP-glucuronosyltransferase
- SN-38G non-cytotoxic SN-38 glucuronide conjugate
- a part of SN-38G excreted in the intestinal tract is deconjugated by ⁇ -glucuronidase contained in the intestinal bacterium to become active SN-38 again, and is reabsorbed through the intestinal epithelial transporter to enter the intestinal liver circulation, intestinal epithelium. It undergoes metabolism and excretion through steps such as glucuronidation by UGT in cells (Non-patent Document 7).
- SN-38 is thought to damage the intestinal mucosa and induce diarrhea. It also affects the bone marrow where cell division is active and has been shown to cause erythrocyte depletion, leukopenia and thrombocytopenia.
- Tumor-side factors involved in CPT-11 sensitivity or resistance include the presence or absence of the mutation and expression level of SN-38 target topoisomerase I, and carboxylesterase activity involved in the conversion of CPT-11 to SN-38 (non- (Patent Document 9), reports on the involvement of transporters (multidrug resistance protein (MRP) -1, MRP-2, breast cancer resistant protein (BCRP) / ABCG2) affecting the amount of intracellular accumulation of CPT-11 and SN-38
- MRP multidrug resistance protein
- BCRP breast cancer resistant protein
- / ABCG2 cell proliferation antigen Ki-67, tumor suppressor gene p53, and the like have also been investigated for their association with the responsiveness to treatment with CPT-11.
- Non-patent Document 10 plasma levels of Tissue inhibitor of metalloproteinase-1 (TIMP-1), which has anti-apoptotic effects, may be significantly correlated with the clinical prognosis of CPT-11 + 5-FU combination therapy for metastatic colorectal cancer Recently reported (Non-Patent Document 11).
- Tissue inhibitor of metalloproteinase-1 Tissue inhibitor of metalloproteinase-1
- Non-patent Document 12 there is a report that no clear relationship was found with the therapeutic response of 11 combination therapy (Non-patent Document 12), and no clear biomarker that can predict the therapeutic response has been established.
- An object of the present invention is to provide an anticancer drug sensitivity determination marker capable of discriminating treatment responsiveness of individual patients and a new cancer treatment means using the same.
- the present inventors cultured human cancer cell lines and comprehensively analyzed changes in intracellular metabolism after exposure to SN-38 using capillary electrophoresis-time-of-flight mass spectrometer (CE-TOFMS).
- CE-TOFMS capillary electrophoresis-time-of-flight mass spectrometer
- a marker for determining sensitivity to an anticancer drug was searched, a peak in which a significant increase in intracellular level was observed after SN-38 exposure in SN-38 low-sensitivity cells or SN-38 exposure in SN-38 high-sensitivity cells
- asparagine and aspartic acid have been found to show changes in intracellular levels different from the control group after SN-38 exposure in SN-38 highly sensitive cells or SN-38 low sensitive cells. It was found that the value calculated by dividing the aspartic acid ratio by the ratio of asparagine to aspartic acid when SN-38 was not exposed was a marker for determining the sensitivity of anticancer agents. Furthermore, the present inventors cultured eight types of human cancer cell lines and searched for anticancer drug sensitivity determination markers using CE-TOFMS for their intracellular metabolites.
- a metabolite whose intracellular level increased with a decrease in sensitivity to cancer drugs was found, and the metabolite was found to be a substance on the metabolic system involving GABA, 1-methyladenosine and glutathione (GSH).
- GABA 1-methyladenosine and glutathione
- the concentration of these metabolites in a biological sample derived from a cancer patient or the ratio of the above metabolite concentrations is used as an index
- the cancer of the cancer patient against anticancer drugs It is possible to determine whether or not there is sensitivity, and it is possible to screen for anticancer drug sensitivity-enhancing agents by using the concentration and fluctuation of these metabolites and the ratio of the metabolite concentration as an index, and
- the present inventors have found that the therapeutic effect of the anticancer agent can be drastically improved by using a cancer drug sensitivity enhancing agent in combination with the anticancer agent that is the subject of sensitivity enhancement, and the present invention has been completed.
- metabolite B A molecule detected as an anion of 99 to 153.00
- the present invention also provides a method for determining sensitivity to an anticancer agent, characterized by measuring the above-mentioned substance in a specimen.
- the present invention also provides a kit for carrying out a method for determining sensitivity to an anticancer agent, comprising a protocol for measuring the above substances. Furthermore, the present invention provides a method for screening an anticancer agent sensitivity enhancer using the expression variation of the substance as an index. Furthermore, this invention provides the anticancer agent sensitivity enhancer obtained by said screening method. Furthermore, this invention provides the composition for cancer treatment which combines said anticancer agent sensitivity enhancer and the anticancer agent used as the object of sensitivity enhancement. Furthermore, this invention provides said substance for determining anticancer agent sensitivity.
- the anticancer drug treatment reactivity of each patient can be accurately determined before anticancer drug administration or early after anticancer drug administration, It is possible to select anti-cancer drugs with higher therapeutic effects, and as a result, it is possible to prevent the progression of cancer and the increase in side effects associated with continuous administration of anti-cancer drugs that cannot be expected to have therapeutic effects, and further reduce the burden on patients. Reduction of medical expenses can also be expected.
- this marker it is possible to screen for drugs that enhance the sensitivity of anticancer drugs, and if the anticancer drug and anticancer drug sensitivity-enhancing agent are used in combination, the effect of cancer treatment will jump dramatically. Improve.
- the measurement reagent of the anticancer drug sensitivity determination marker of the present invention is useful as an anticancer drug sensitivity determination reagent.
- FIG. 3 is a graph showing changes over time in the average survival rate of HT-29 and HCT-116 cells upon exposure to 50 nmol / L SN-38. It is a figure which shows the time-dependent change of the intracellular level of the metabolite A after SN-38 exposure in HT-29 and HCT-116. It is a figure which shows the time-dependent change of the intracellular level of the metabolite B after SN-38 exposure in HT-29 and HCT-116. It is a figure which shows the time-dependent change of the intracellular level of 2-methylbutyroylcarnitine after SN-38 exposure in HT-29 and HCT-116.
- HCT-116 is a view showing the change over time in the intracellular levels of BH 2 after SN-38 exposure. It is a figure which shows the time-dependent change of the intracellular level of the metabolite D after SN-38 exposure in HT-29 and HCT-116. It is a figure which shows the time-dependent change of the intracellular level of glycerol 3-phosphate after SN-38 exposure in HT-29 and HCT-116. It is a figure which shows the time-dependent change of the intracellular level of GABA after SN-38 exposure in HT-29 and HCT-116.
- Anticancer drug sensitivity determination markers in the present invention are metabolites A, B, D, glycerol triphosphate, dihydrobiopterin, GABA, lactic acid, asparagine, aspartic acid, 2-methylbutyroylcarnitine, 1-methyladenosine, glutathione And a molecule selected from substances on the metabolic system in which these molecules are involved (hereinafter also referred to as “metabolic substances”).
- the molecule to be detected In addition, all substances in the metabolic system that change the concentration of these molecules are included. These substances include substances that enhance and inhibit metabolism to these molecules, and promote metabolism from these molecules. Substances, inhibiting substances, etc. are mentioned.
- One of the anticancer drug sensitivity determination markers in the present invention is glycerol triphosphate or a substance on a metabolic system (also referred to as a glycerol 3-phosphate metabolite) involved in the glycerol triphosphate.
- a metabolic system also referred to as a glycerol 3-phosphate metabolite
- all substances that vary the concentration of glycerol triphosphate in the metabolic system are included, substances that enhance metabolism, substances that inhibit metabolism, substances that promote metabolism from glycerol triphosphate, Inhibiting substances are included. Of these, glycerol triphosphate is particularly preferred.
- One of the anticancer drug sensitivity determination markers in the present invention is dihydrobiopterin (BH 2 ) or a substance on the metabolic system (also referred to as BH 2 metabolite), which includes BH 2 in addition to BH 2 . Included are all substances that change the concentration of BH 2 in the metabolic system, such as substances that enhance metabolism to BH 2 , substances that inhibit, substances that promote metabolism from BH 2, and substances that inhibit. Of these, BH 2 is particularly preferred.
- GABA anticancer drug susceptibility determination markers in the present invention
- GABA or a substance on the metabolic system (also referred to as GABA metabolic substance) in which this is involved, and as this substance, in addition to GABA, the concentration of GABA in the metabolic system All substances that change the pH are included, including substances that enhance metabolism to GABA, substances that inhibit, substances that promote metabolism from GABA, and substances that inhibit. Of these, GABA is particularly preferred.
- One of the anticancer drug sensitivity determination markers in the present invention is lactic acid or a substance on a metabolic system (also referred to as a lactic acid metabolic substance) in which this is involved, and as the substance, in addition to lactic acid, the concentration of lactic acid in the metabolic system All substances that change the pH are included, including substances that enhance metabolism to lactic acid, substances that inhibit, substances that promote metabolism from lactic acid, and substances that inhibit. Of these, lactic acid is particularly preferred.
- One of the anticancer drug sensitivity determination markers in the present invention is asparagine, aspartic acid, or a substance on a metabolic system involving these. These ratios are important in the case of asparagine and aspartic acid, specifically the ratio of asparagine to aspartic acid calculated from the concentrations of asparagine and aspartic acid, more specifically asparagine when exposed to anticancer drugs. Calculated by dividing the ratio of aspartic acid to asparagine to aspartic acid without exposure to anticancer drugs
- asparagine and aspartic acid-related substances can be used as substances used for calculating the ratio. Include all substances that change the concentration of asparagine and aspartic acid in the metabolic system, asparagine, substances that enhance metabolism to aspartate, inhibitors, asparagine, substances that promote metabolism from aspartate, inhibit Examples include substances. Of these, asparagine and aspartic acid are particularly preferred.
- One of the anticancer drug susceptibility determination markers in the present invention is 2-methylbutyroylcarnitine or a substance on a metabolic system (also referred to as 2-methylbutyroylcarnitine metabolite) that involves this,
- 2-methylbutyroylcarnitine a substance on a metabolic system
- all substances that change the concentration of 2-methylbutyroylcarnitine in the metabolic system are included, and substances that enhance or inhibit metabolism to 2-methylbutyroylcarnitine, 2- Substances that promote or inhibit metabolism from methylbutyroylcarnitine.
- 2-methylbutyroylcarnitine is particularly preferred.
- One of the anticancer drug sensitivity determination markers in the present invention is 1-methyladenosine or a substance on a metabolic system (also referred to as a 1-methyladenosine metabolite), which includes 1-methyladenosine.
- a 1-methyladenosine metabolite also referred to as a 1-methyladenosine metabolite
- all substances that change the concentration of 1-methyladenosine in the metabolic system are included, substances that enhance metabolism, substances that inhibit metabolism, substances that promote metabolism from 1-methyladenosine, Inhibiting substances are included. Of these, 1-methyladenosine is particularly preferred.
- One of the anti-cancer drug sensitivity determination markers in the present invention is glutathione or a substance on the metabolic system (also referred to as glutathione metabolic substance) in which this is involved, and the substance includes glutathione and glutathione concentration in the metabolic system. All substances that change the pH are included, including substances that enhance metabolism to glutathione, substances that inhibit, substances that promote metabolism from glutathione, and substances that inhibit.
- glutathione, hypotaurine, 1-methylnicotinamide, taurine, glutathione disulfide (GSSG), S-adenosylhomocysteine, nicotinamide, ⁇ -glutamylcysteine ( ⁇ -Glu-Cys), and spermine are preferred, and glutathione is particularly preferred.
- Hypotaurine and 1-methylnicotinamide are preferred.
- the metabolite A, B, 2-methylbutyroylcarnitine showed a significant increase in intracellular levels after exposure to SN-38 in HT-29, which is less sensitive to SN-38. .
- HCT-116 which is highly sensitive to SN-38, no significant change in intracellular level was observed. Therefore, these substances are particularly useful as markers for determining sensitivity to anticancer agents such as CPT-11 and SN-38.
- Metabolite D, glycerol triphosphate, BH 2 , and lactic acid showed a significant increase in intracellular levels in HCT-116, which is highly sensitive to SN-38 after exposure to SN-38. It was. On the other hand, in HT-29, which is less sensitive to SN-38, there was no significant change in intracellular level. Therefore, these substances are particularly useful as markers for determining sensitivity to anticancer agents such as CPT-11 and SN-38.
- GABA showed a marked increase in intracellular level in HT-29, which is less sensitive to SN-38, after exposure to SN-38.
- HCT-116 which is highly sensitive to SN-38, no significant change in intracellular level was observed.
- intracellular level was high in HT-29 having a low sensitivity to SN-38, and intracellular level was low in HCT-116 having a high sensitivity to SN-38.
- GABA is particularly useful as a marker for determining sensitivity to anticancer agents such as CPT-11 and SN-38.
- Asparagine as shown in the examples below, showed a variation in intracellular levels of HCT-116, which is highly sensitive to SN-38, different from the control group after SN-38 exposure, but HT-, which is sensitive to SN-38. In 29, there was no difference in intracellular level between the SN-38 exposed group and the control group.
- aspartic acid as shown in the examples described later, showed a change in intracellular level different from the control group after exposure to SN-38 in HT-29, which was SN-38 low sensitive, but it was highly sensitive to SN-38. In one HCT-116, there was no difference in intracellular level between the SN-38 exposed group and the control group.
- 1-Methyladenosine and glutathione metabolites were examined using 8 types of human cancer cell lines, as shown in the examples below. As a result, the sensitivity of SN-38 to these substances in cells decreased. Level increased. Therefore, 1-methyladenosine and glutathione metabolites are particularly useful as markers for determining sensitivity to anticancer agents such as CPT-11 and SN-38.
- the anticancer agent that is a target of the anticancer drug sensitivity determination marker of the present invention is not particularly limited, and examples thereof include CPT-11, SN-38, oxaliplatin, cyclophosphamide, ifosfamide, Thiotepa, melphalan, busulfan, nimustine, ranimustine, dacarbazine, procarbazine, temozolomid, temozolomid, temozol , Nedaplatin, methotrexate method, pemetrexed, fluorouracil, tegafur / uracil, doxyfluridine, tegafur / teracil, tegafur / cite Enocitabine, gemcitabine, 6-mercaptopurine, fludarabine, pentostatin, cladribine, hydroxyurea (hy) roxyurea, doxorubicin, epirubicin, daunorubicin, idarubi
- Medroxyprogesterone anastrozole, exemestane, letrozole, rituximab, imatinib, gefitinib (gefinib) inib), gemtuzumab ozogamicin (gemtuzumab ozogamicin), bortezomib (bortezomib), erlotinib (erlotinib), cetuximab (cetuximab), bevacizumab (bevacizumab), sunitinib (sunitinib), sorafenib (sorafenib), dasatinib (dasatinib), panitumumab (panitumumab) , Asparaginase, tretinoin, arsenic trioxide, or salts thereof, or active metabolites thereof, among which plant alkaloid anticancer agents such as CPT-11, SN-38 or a salt thereof is preferred.
- these metabolic substances in a sample may be measured.
- the specimen include biological samples derived from subjects having cancer (cancer patients) such as blood, serum, plasma, urine, tumor tissue / cells, ascites, pleural effusion, cerebrospinal fluid, stool, sputum, and the like. Serum is particularly preferred.
- lip, oral and pharyngeal cancer typified by pharyngeal cancer
- digestive organ cancer typified by esophageal cancer
- stomach cancer colon / rectal cancer
- lung cancer Respiratory and intrathoracic organ cancer, bone and joint cartilage cancer, cutaneous malignant melanoma, squamous cell carcinoma and other skin cancers, mesothelioma and mesothelioma Tissue cancer, breast cancer, uterine cancer, female genital cancer represented by ovarian cancer, male genital cancer represented by prostate cancer, urinary tract cancer represented by bladder cancer, brain tumor Representative eye, brain and central nervous system cancer, thyroid and other endocrine adenocarcinoma, non-Hodgkin lymphoma, lymphoid leukemia, lymphoid tissue, hematopoietic tissue and related tissue cancer, and these as the primary focus Include metastatic tissue cancers, especially non-small cell lung cancer, small cell lung cancer, small cell lung cancer, small cell lung
- the means for measuring these metabolic substances in a sample may be appropriately determined depending on the substance to be measured.
- CE-TOFMS various mass spectrometers such as gas chromatography-mass spectrometry (GC-MS), HPLC, immunological It can be measured by a measurement method, biochemical measurement method or the like.
- GC-MS gas chromatography-mass spectrometry
- HPLC HPLC
- immunological It can be measured by a measurement method, biochemical measurement method or the like.
- these metabolisms in biological samples derived from cancer patients before and after the administration of the anticancer drug are used. If the concentration of these metabolic substances increases after administration compared to before administration of the anticancer drug, the cancer is not anticancer drug sensitive and its metabolism before and after administration of the anticancer drug. If the concentration of the system substance does not change, it can be determined that the cancer is sensitive to an anticancer drug. In the early stage after administration of an anticancer drug, if the concentration of these metabolic substances is determined to be higher than a predetermined standard concentration, the cancer is against the targeted anticancer drug. It can be determined that there is no sensitivity.
- the anticancer drug sensitivity determination marker in the present invention not only determines the anticancer drug treatment responsiveness, but also prevents an increase in side effects associated with continuous administration of an anticancer drug that cannot be expected to have a medicinal effect. Contribute greatly.
- the cancer is sensitive to the anticancer drug. If the concentration of these metabolic substances increases after administration compared to before administration of the anticancer drug, the cancer is sensitive to the anticancer drug. If the concentration of the metabolic substance does not change, it can be determined that the cancer is not sensitive to an anticancer drug. In the early stage after administration of an anticancer drug, if the concentration of these metabolic substances is determined to be lower than a predetermined standard concentration, the cancer is against the targeted anticancer drug. It can be determined that there is no sensitivity.
- the anticancer drug sensitivity determination marker in the present invention not only determines the anticancer drug treatment responsiveness, but also prevents an increase in side effects associated with continuous administration of an anticancer drug that cannot be expected to have a medicinal effect. Contribute greatly.
- the concentration of these metabolic substances in a biological sample derived from a cancer patient before and after administration of the anticancer agent is measured, and the anticancer agent is measured. If the concentration of these metabolic substances increases after administration compared to before administration, the cancer is not sensitive to anticancer drugs, and if the concentration of these metabolic substances does not change before and after administration of anticancer drugs, Can be determined to be sensitive to anticancer drugs. In addition, if the concentration of these metabolic substances is determined to be higher than a predetermined standard concentration before or after the administration of the anticancer agent, the cancer is the target anticancer agent. It can be determined that there is no sensitivity to.
- the anticancer drug sensitivity determination marker in the present invention not only determines the anticancer drug treatment responsiveness, but also prevents an increase in side effects associated with continuous administration of an anticancer drug that cannot be expected to have a medicinal effect. Contribute greatly.
- the concentrations of asparagine and aspartic acid in biological samples derived from cancer patients before and after administration of the anticancer drug If the ratio of asparagine to aspartic acid after administration is higher than that before administration of the anticancer drug, the cancer is sensitive to the anticancer drug, and asparagine to aspartic acid before and after administration of the anticancer drug. If the ratio decreases, it can be determined that the cancer is not sensitive to anticancer drugs. In addition, if the ratio of asparagine to aspartic acid is determined to be lower than a predetermined standard at an early stage after administration of the anticancer drug, the cancer is sensitive to the target anticancer drug.
- the anticancer drug sensitivity determination marker in the present invention not only determines the anticancer drug treatment responsiveness, but also prevents an increase in side effects associated with continuous administration of an anticancer drug that cannot be expected to have a medicinal effect. Contribute greatly.
- the concentration of these metabolite substances should be higher than a predetermined standard concentration before administration of the anticancer drug. If it has the determined concentration, it can be determined that the cancer is not sensitive to the anticancer agent of interest. If there is no sensitivity to the targeted anticancer drug, its efficacy cannot be expected, and if the administration of an anticancer drug that cannot be expected to have such efficacy is continued, There is concern about progression and increased side effects.
- the anticancer drug sensitivity determination marker in the present invention not only determines the anticancer drug treatment responsiveness, but also prevents an increase in side effects associated with continuous administration of an anticancer drug that cannot be expected to have a medicinal effect. Contribute greatly.
- kits including a protocol for measuring these metabolic substances in a sample.
- the kit includes a reagent for measuring these metabolic substances, a method for using the measuring reagent, a standard for determining the presence or absence of anticancer drug sensitivity, and the like.
- These standards include standard concentrations and standard ratios of these metabolites, concentrations and ratios that are judged to be high, concentrations and ratios that are judged to be low, factors that affect measurement results, and the extent of the impact. These concentrations can be set for each target anticancer agent. Using the reference, it can be determined as described above.
- an anticancer drug sensitivity-enhancing agent can be screened. That is, substances that reduce the concentration of metabolites A, B, 2-methylbutyroylcarnitine, GABA, 1-methyladenosine, and glutathione metabolites in vitro or in vivo before exposure to anticancer agents, anticancer agents Substances that suppress fluctuations or reduce concentrations after exposure increase sensitivity to anticancer drugs.
- intracellular metabolites A, B, 2-methylbutyroylcarnitine, GABA, 1-methyladenosine, glutathione The substance that decreases the concentration of the metabolic substance is a substance that enhances the sensitivity of the anticancer drug (anticancer drug sensitivity enhancer). In vitro, it also suppresses changes in intracellular metabolites A, B, 2-methylbutyroylcarnitine, GABA, 1-methyladenosine, and glutathione metabolites after exposure to anticancer drugs in various cancer cell lines.
- the substance that enhances the sensitivity of the anticancer drug is an anticancer drug sensitivity enhancer.
- anticancer agent sensitivity enhancer Can be screened. That is, a substance that promotes fluctuation or increases the concentration of metabolite D, glycerol triphosphate, BH 2 , and lactic acid after exposure to an anticancer agent in vitro or in vivo enhances anticancer agent sensitivity.
- substances that promote changes in metabolites D, glycerol triphosphate, BH 2 , and lactic acid in cells after exposure to anticancer agents in various cancer cell lines are sensitive to the anticancer agents.
- anticancer agent sensitivity enhancer It is a substance (anticancer agent sensitivity enhancer) that enhances In vivo, substances that promote or increase the concentration of metabolites D, glycerol triphosphate, BH 2 , and lactic acid after exposure to anticancer drugs in cancer-bearing animals are sensitive to the anticancer drugs. It is a substance (anticancer agent sensitivity enhancer) that enhances
- anticancer drug sensitivity-enhancing agents can be screened by using asparagine to aspartic acid ratio change after exposure to an anticancer drug, specifically, an increase in the ratio as an index. That is, a substance that increases the ratio of asparagine and aspartic acid concentration after exposure to an anticancer agent in vitro or in vivo enhances the sensitivity of the anticancer agent. For example, in vitro, substances that increase the ratio of asparagine and aspartic acid concentrations in cells after exposure to anticancer drugs in various cancer cell lines are substances that enhance the sensitivity of the anticancer drugs (anticancer drugs). Agent sensitivity enhancer).
- a substance that increases the ratio of asparagine and aspartic acid concentration after exposure to an anticancer drug in a cancer-bearing animal is a substance that enhances the sensitivity of the anticancer drug (an anticancer drug sensitivity enhancer).
- an anticancer drug sensitivity enhancer As the ratio of these concentrations, a value calculated by dividing the ratio of asparagine to aspartic acid at the time of anticancer drug exposure by the ratio of asparagine to aspartic acid at the time of non-anticancer drug exposure may be used.
- an anticancer agent sensitivity-enhancing agent can be screened with high sensitivity and sensitivity.
- antimetabolite drugs can be screened using metabolites A, B, 2-methylbutyroylcarnitine, GABA, 1-methyladenosine, and glutathione metabolites as indicators. That is, if the concentration of these metabolic substances varies in vitro or in vivo depending on a certain substance, the substance is an anticancer agent. For example, in vitro, the concentration of metabolites A, B, 2-methylbutyroylcarnitine, GABA, 1-methyladenosine and glutathione metabolites after exposure of a substance to various cancer cell lines is higher than before exposure. If it fluctuates, the substance is an anticancer drug.
- the substance is an anticancer agent.
- anticancer drugs that can be expected to have a medicinal effect, the concentration fluctuations of these metabolic substances appear faster than the tumor shrinkage or cell killing effect. It can be determined whether or not the substance is useful as an anticancer agent. A significant effect can be expected from the viewpoint of reducing labor and costs associated with the development of anticancer drugs.
- anticancer agents can be screened using metabolites D, glycerol triphosphate, BH 2 , and lactic acid as indices. That is, if the concentration of these metabolic substances is increased by a certain substance in vitro or in vivo, the substance is an anticancer agent. For example, in vitro, if a substance is exposed to various cancer cell lines and the concentrations of metabolite D, glycerol triphosphate, BH 2 , and lactic acid metabolites increase compared to before the exposure, It is a cancer drug. Moreover, if the concentration of these metabolic substances increases after administering a substance to a cancer-bearing animal, the substance is an anticancer agent.
- anticancer drugs that can be expected to have a medicinal effect, the increase in the concentration of these metabolic substances appears earlier than the tumor reduction or cell killing effect. It can be determined whether or not the substance is useful as an anticancer agent. A significant effect can be expected from the viewpoint of reducing labor and costs associated with the development of anticancer drugs.
- anticancer agents can be screened using the ratio of aspartic acid to aspartic acid as an index. That is, if the ratio of asparagine to aspartic acid concentration is increased by a certain substance in vitro or in vivo, the substance is an anticancer agent. For example, in vitro, if a substance is exposed to various cancer cell lines and the ratio of asparagine to aspartic acid concentration is increased compared to before exposure, the substance is an anticancer agent. In addition, if a ratio of asparagine and aspartic acid concentration increases after administering a substance to a cancer-bearing animal, the substance is an anticancer agent.
- the increase in the ratio of asparagine and aspartic acid appears faster than the tumor shrinkage or cell killing effect, so screening using the ratio of asparagine and aspartic acid as an index is more effective.
- the substance is useful as an anticancer agent can be determined by a short examination. A significant effect can be expected from the viewpoint of reducing labor and costs associated with the development of anticancer drugs.
- a ratio of asparagine and aspartic acid concentration a value calculated by dividing the ratio of asparagine to aspartic acid when the test substance is exposed by the ratio of asparagine to aspartic acid when the test substance is not exposed may be used.
- anticancer agents can be screened with high sensitivity and sensitivity.
- the combined form of the anticancer agent sensitivity-enhancing agent and the anticancer agent targeted for sensitivity enhancement may be a single composition containing both of these components. There may be. In addition, these components may be different administration routes.
- Anticancer agents to be used here are the same as those described above, and include CPT-11, SN-38, oxaliplatin, cyclophosphamide, ifosfamide, thiotepa, melamine.
- Example 1 (1) Method (a) Cells used Two types of human colon cancer cell lines (HCT-116, HT-29) were used. These cells were obtained from Yakult Honsha. The culture was performed in a medium (Doulbecco's modified Eagle's Medium, 10% Fetal Bovine Serum) at 37 ° C., 5% CO 2 with ⁇ 100 mm / Tissue Culture Dish (IWAKI). (B) Drug SN-38 bulk powder was obtained from Yakult Honsha Co., Ltd. SN-38 was dissolved in DMSO and diluted in each experiment so that the concentration of DMSO in the medium was 0.1% or less.
- a Cells used Two types of human colon cancer cell lines (HCT-116, HT-29) were used. These cells were obtained from Yakult Honsha. The culture was performed in a medium (Doulbecco's modified Eagle's Medium, 10% Fetal Bovine Serum) at 37 ° C., 5% CO 2 with ⁇ 100 mm / Tissue Culture
- composition estimation was advanced using analysis software Analyst TM QS (Applied Biosystems, Inc.).
- KEGG Life System Information Integrated Database (http://www.kegg.jp/) prepared by Kyoto University
- this peak was found to be glycerol 3-phosphorus. It was found to be an acid.
- the examination using the glycerol triphosphate preparation also confirmed the coincidence of the migration time of capillary electrophoresis.
- the estimation of the composition was advanced using CE-QTOFMS.
- a substance estimated from this ionic composition was searched using Human Metabolome Database (http://www.hmdb.ca/), it was found that this peak was dihydrobiopterin.
- a study using dihydrobiopterin preparations also confirmed the coincidence of capillary electrophoresis migration times.
- the estimation of the composition was advanced using the analysis software Analyst TM QS (Applied Biosystems, Inc.).
- KEGG Life System Information Integration Database (http://www.kegg.jp/) created by Kyoto University, a substance estimated from this ionic composition was searched, and this peak was lactic acid. It has been found. Examination using a lactic acid sample confirmed that the migration times of capillary electrophoresis were consistent.
- both cells were compared for the control group, and a peak with a large difference was extracted.
- a characteristic change was shown, which was considered to be a metabolite associated with SN-38 sensitivity (FIG. 8).
- the estimation of the composition was advanced using analysis software Analyst TM QS (Applied Biosystems, Inc.).
- the ion composition of m / z 104.070 as the candidate peak was C 4 H 10 NO 2 .
- KEGG Life System Information Integrated Database
- this peak was found to be ⁇ -aminobutyric. It was found to be acid (GABA). Examination using the GABA standard confirmed that the migration time of capillary electrophoresis was consistent.
- the estimation of the composition was advanced using analysis software Analyst TM QS (Applied Biosystems, Inc.).
- KEGG Life System Information Integrated Database
- the estimation of the composition was advanced using analysis software Analyst TM QS (Applied Biosystems, Inc.).
- KEGG Life System Information Integration Database (http://www.kegg.jp/) created by Kyoto University, we searched for substances estimated from this ion composition. It turned out to be.
- aspartic acid preparations it was confirmed that the migration times of capillary electrophoresis coincided.
- Example 2 (1) Method (a) Cells used Eight kinds of human colon cancer cell lines (HCT-116, HT-29, HCT-15, Lovo, LS174T, SW480, SW620, WiDr) were used. HCT-116 and HT-29 from Yakult Honsha Co., Ltd., Lovo, SW480 and WiDr from Dainippon Sumitomo Pharma Co., Ltd., HCT-15 and LS174T from Tohoku University Institute of Aging Medicine, SW620 for Sumisho Obtained from Pharma International Co., Ltd. (B) Drug SN-38 bulk powder was obtained from Yakult Honsha Co., Ltd. SN-38 was dissolved in DMSO and diluted in each experiment so that the concentration of DMSO in the medium was 0.1% or less.
- HCT-116 and HT-29 from Yakult Honsha Co., Ltd.
- Lovo, SW480 and WiDr from Dainippon Sumitomo Pharma Co., Ltd.
- HCT-15 and LS174T from To
- Example 3 (1) Method The experiment similar to Example 2 was repeated once again, and further detailed analysis was performed on the data obtained from a total of three experiments. The peak detected by CE-TOFMS from each cell sample was compared with 278 sample data whose m / z and migration time had already been confirmed, and 146 metabolisms confirmed to be detected in any cell. The thing was identified. With respect to these 146 metabolites, the relationship between the intracellular amount of each of the eight types of human colon cancer cells and the Log [IC 50 ] of each cell was examined by single regression analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Electrochemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
進行性・転移大腸癌に対する化学療法は、1990年代に登場したCPT-11、オキサリプラチンなどのkey drugと、それまで大腸癌治療の中心的薬剤であったフルオロウラシル(5-FU)を中心とするフッ化ピリミジン製剤とを併用することにより、生存率をはじめとする臨床成績が劇的に改善された。しかしそれでもなお奏効率はおよそ50%程度であり、重篤な副作用という高リスクを冒して抗がん剤が投与された患者の半分では効果が得られていないのが現状であり、個々の治療反応性(レスポンダー・ノンレスポンダー)を判別する抗がん剤感受性予測マーカーの確立は急務である。
一般的に、がん化学療法の治療スケジュールは長期に渡り、副作用の発現を見ながら何クールか繰り返し治療を行った後で、効果が得られているか、そのまま投与を続けるべきか判断するが、それまでには長い時間と高額な医療費がかかり、副作用の発現も起こっているのが事実である。よって、個々の患者に対し、効果が得られるかどうかを治療前あるいは治療早期に予測できる手段があれば、患者の負担や副作用の発現を軽減し、医療費を削減することができる。
重篤な下痢や好中球減少症などの副作用は、UGT1A1遺伝多型がもたらすSN-38体内曝露量の変化が一因であることが示されている。しかし治療効果に関しては、プロドラッグであるCPT-11から活性代謝物SN-38への変換とその解毒、さらに腸管循環の過程におけるSN-38の再生成や、CPT-11自体の代謝と代謝物からのSN-38の生成といった体内動態の複雑性により、また、抗腫瘍効果が腫瘍側の要因により規定されることが多いため、薬物動態により治療効果を予測できるとする報告は未だなされていない。末梢血単核球細胞のカルボキシルエステラーゼmRNA発現量がSN-38とSN-38GのAUC比とは相関するものの腫瘍縮小効果とは相関がなかったとする報告もなされている(非特許文献8)。
また、本発明は、検体中の上記の物質を測定することを特徴とする抗がん剤感受性の判定方法を提供するものである。
また、本発明は、上記の物質を測定するためのプロトコールを含むことを特徴とする抗がん剤感受性の判定方法を実施するためのキットを提供するものである。
さらに本発明は、上記の物質の発現変動を指標とする抗がん剤感受性亢進剤のスクリーニング方法を提供するものである。
さらにまた本発明は、上記のスクリーニング方法により得られた抗がん剤感受性亢進剤を提供するものである。
さらに本発明は、上記の抗がん剤感受性亢進剤と、感受性亢進の対象となる抗がん剤とを組み合せてなるがん治療用組成物を提供するものである。
さらに本発明は、抗がん剤感受性を判定するための上記の物質を提供するものである。
また、抗がん剤投与後初期の段階において、これら代謝系物質の濃度が所定の標準濃度より高いと判断される濃度を有する場合は、そのがんは対象とする抗がん剤に対して感受性がないと判定できる。対象とする抗がん剤に対して感受性を有さない場合は、その薬効を期待することができず、このような薬効の期待できない抗がん剤の投与が続けられた場合、がんの進行、副作用の増大が危惧される。このように、本発明における抗がん剤感受性判定マーカーは、抗がん剤治療反応性の判定のみならず、薬効の期待できない抗がん剤の継続投与に伴う副作用の増大を防ぐことにも大きく貢献する。
また、抗がん剤投与後初期の段階において、これら代謝系物質の濃度が所定の標準濃度より低いと判断される濃度を有する場合は、そのがんは対象とする抗がん剤に対して感受性がないと判定できる。対象とする抗がん剤に対して感受性を有さない場合は、その薬効を期待することができず、このような薬効の期待できない抗がん剤の投与が続けられた場合、がんの進行、副作用の増大が危惧される。このように、本発明における抗がん剤感受性判定マーカーは、抗がん剤治療反応性の判定のみならず、薬効の期待できない抗がん剤の継続投与に伴う副作用の増大を防ぐことにも大きく貢献する。
また、抗がん剤投与前あるいは投与後初期の段階において、これら代謝系物質の濃度が所定の標準濃度より高いと判断される濃度を有する場合は、そのがんは対象とする抗がん剤に対して感受性がないと判定できる。対象とする抗がん剤に対して感受性を有さない場合は、その薬効を期待することができず、このような薬効の期待できない抗がん剤の投与が続けられた場合、がんの進行、副作用の増大が危惧される。このように、本発明における抗がん剤感受性判定マーカーは、抗がん剤治療反応性の判定のみならず、薬効の期待できない抗がん剤の継続投与に伴う副作用の増大を防ぐことにも大きく貢献する。
また、抗がん剤投与後初期の段階において、アスパラギンの対アスパラギン酸比が所定の基準より低いと判断される数値を有する場合は、そのがんは対象とする抗がん剤に対して感受性がないと判定できる。対象とする抗がん剤に対して感受性を有さない場合は、その薬効を期待することができず、このような薬効の期待できない抗がん剤の投与が続けられた場合、がんの進行、副作用の増大が危惧される。このように、本発明における抗がん剤感受性判定マーカーは、抗がん剤治療反応性の判定のみならず、薬効の期待できない抗がん剤の継続投与に伴う副作用の増大を防ぐことにも大きく貢献する。
なお、アスパラギンとアスパラギン酸濃度の比として、被検査物質曝露時のアスパラギンの対アスパラギン酸比を被検査物質非曝露時のアスパラギンの対アスパラギン酸比で除することによって算出される値を用いてもよく、この値を用いた場合、感度よく鋭敏に抗がん剤をスクリーニングすることができる。
(1)方法
(a)使用細胞
2種類のヒト大腸癌細胞株(HCT-116、HT-29)を用いた。これらの細胞は株式会社ヤクルト本社より入手した。
培養は、φ100mm/Tissue Culture Dish(IWAKI)にて、培地(Doulbecco‘s modified Eagle’s Medium、10% Fetal Bovine Serum)、37℃、5%CO2の条件下にて行った。
(b)薬剤
SN-38原末は、株式会社ヤクルト本社より入手した。SN-38はDMSOに溶解し、各実験で培地中のDMSOの濃度が0.1%以下となるように希釈して使用した。
両細胞について、50nmol/LのSN-38に24、48、72時間曝露後の細胞生存率をMTS assay(CellTiter96TMAQueous One Solution Cell Proliferation Assay、Promega)にて評価した。感受性の評価は異なる継代数の細胞にてtriplicateで3回行い、その平均値と標準偏差を算出した。
両細胞に対して、50nmol/LのSN-38を含む培地に交換することにより抗がん剤曝露を開始した(SN-38のみを除いた培地を用いたものをコントロール群とした)。0hr、3hr、8hr、24hr曝露後に氷上にて5%マンニトール(4℃)で細胞を洗浄後、素早くメタノール(4℃、内部標準物質含有)を添加することにより酵素を失活させ、-80℃で保存した。なお、細胞数算出用の細胞を代謝物抽出用の細胞とは別に準備し、同様の処理を行った後セルカウントを行い、細胞数補正に用いた。
-80℃保存メタノール溶液に、クロロホルムとミリQ水を加え液―液抽出を行い、夾雑成分を除去した。代謝物を含む水―メタノール層を採取し、分画分子量5000Daの遠心限外ろ過フィルターを用いて除タンパクを行った後、ろ液を減圧乾燥し、-80℃にて保存した。測定直前にミリQ水に溶解させ、メタボローム測定に供した。
細胞内代謝物の網羅的測定はAgilent Technologies社のキャピラリー電気泳動―飛行時間型質量分析計(CE-TOFMS)にて行った。陽イオン性代謝物の網羅的測定ではキャピラリーの出口が陰極となるように電圧を印加し、また、陰イオン性代謝物の網羅的測定ではキャピラリーの出口が陽極となるように電圧を印加し、m/z=50~1000の代謝物を一斉に定量分析した。
MTS assayにより50nmol/LのSN-38曝露後の経時的な細胞生存率について検討したところ、各細胞の生存率は24hr曝露後においてはほとんど差が認められなかった。しかし、曝露時間が長くなるにつれて各細胞の生存率は低下し、その差は経時的に拡大した。72hr曝露後における細胞生存率はHT-29で約85%、HCT-116で約35%となり、HT-29がHCT-116に比べSN-38低感受性であることが確認された(図1)。
(1)SN-38曝露後、HT-29で細胞内レベルの顕著な上昇が認められた代謝物・m/z=149.05~149.06(陰イオン)
・m/z=152.99~153.00(陰イオン)
・m/z=246.16~246.17(陽イオン)
(2)SN-38曝露後、HCT-116で細胞内レベルの顕著な上昇が認められた代謝物
m/z=171.00(陰イオン)
m/z=240.10~240.11(陽イオン)
m/z=724.34~724.35(陽イオン)
m/z=89.02(陰イオン)
(3)HCT116でSN-38曝露後コントロール群と異なる細胞内レベルの変動を示すピーク
m/z=133.06(陽イオン)
(4)HT-29でSN-38曝露後コントロール群と異なる細胞内レベルの変動を示すピーク
m/z=134.04(陽イオン)
また、m/z=152.99~153.00(陰イオン)のピークに関して、CE-QTOFMSを用いて組成の推定を進めた。その結果、m/z=152.99~153.00のイオン組成はC3H6O5Pと考えられた。
また、m/z=246.16~246.17(陽イオン)のピークに関して、CE-QTOFMSを用いて組成の推定を進めた。その結果、m/z=246.16~246.17のイオン組成はC12H24NO4であった。Human Metabolome Database(http://www.hmdb.ca/)を用いて、このイオン組成から推定される物質を検索したところ、このピークが2-メチルブチロイルカルニチンであることが判明した。2-メチルブチロイルカルニチン標品を用いた検討により、キャピラリー電気泳動の移動時間の一致も確認された。
また、m/z=240.10~240.11(陽イオン)のピークに関して、CE-QTOFMSを用いて組成の推定を進めた。その結果、m/z=240.10~240.11のイオン組成はC9H14N5O3であった。Human Metabolome Database(http://www.hmdb.ca/)を用いて、このイオン組成から推定される物質を検索したところ、このピークがジヒドロビオプテリンであることが判明した。ジヒドロビオプテリン標品を用いた検討により、キャピラリー電気泳動の移動時間の一致も確認された。
また、m/z=134.04のピークに関して、解析ソフトAnalystTM QS(Applied Biosystems,Inc.)を用いて、組成の推定を進めた。親ピークに対するアイソトープの割合、精密質量等の情報から組成を特定した結果、候補ピークとしたm/z=134.04のイオン組成はC4H8NO4であった。京都大学が作製したKEGG:生命システム情報統合データベース(http://www.kegg.jp/)の代謝データベースを用いて、このイオン組成から推定される物質を検索したところ、このピークがアスパラギン酸であることが判明した。アスパラギン酸標品を用いた検討により、キャピラリー電気泳動の移動時間の一致も確認された。
(1)方法
(a)使用細胞
8種類のヒト大腸癌細胞株(HCT-116、HT-29、HCT-15、Lovo、LS174T、SW480、SW620、WiDr)を用いた。HCT-116、HT-29は株式会社ヤクルト本社より、Lovo、SW480、WiDrは大日本住友製薬株式会社より、HCT-15、LS174Tは東北大学加齢医学研究所医用細胞資源センターより、SW620は住商ファーマインターナショナル株式会社より入手した。
(b)薬剤
SN-38原末は、株式会社ヤクルト本社より入手した。SN-38はDMSOに溶解し、各実験で培地中のDMSOの濃度が0.1%以下となるように希釈して使用した。
各細胞について、0nmol/L~5μmol/LのSN-38に72時間曝露後の細胞生存率をMTS assay(CellTiter96TMAQueous One Solution Cell Proliferation Assay、Promega)にて評価し、IC50値(SN-38未処理wellに対して細胞数を50%抑制する濃度)を算出して各細胞におけるSN-38感受性とした。実験はtriplicateで2回行った。
定常状態における各細胞に対して、培地を除去し氷上にて5%マンニトール(4℃)で細胞を洗浄後、素早くメタノール(4℃、内部標準物質含有)を添加することにより酵素を失活させ、-80℃で保存した。なお、細胞数算出用の細胞を代謝物抽出用の細胞とは別に準備し、同様の処理を行った後セルカウントを行い、細胞数補正に用いた。実験はtriplicateで2回行った。
-80℃保存メタノール溶液に、クロロホルムとミリQ水を加え液―液抽出を行い、夾雑成分を除去した。代謝物を含む水―メタノール層を採取し、分画分子量5000Daの遠心限外ろ過フィルターを用いて除タンパクを行った後、ろ液を減圧乾燥し、-80℃にて保存した。測定直前にミリQ水に溶解させ、メタボローム測定に供した。
細胞内代謝物の網羅的測定はAgilent Technologies社のキャピラリー電気泳動―飛行時間型質量分析計(CE-TOFMS)にて行った。陽イオン性代謝物の網羅的測定ではキャピラリーの出口が陰極となるように電圧を印加し、陰イオン性代謝物の網羅的測定ではキャピラリーの出口が陽極となるように電圧を印加し、m/z=50~1000の代謝物を一斉に定量分析した。
各細胞サンプルからCE-TOFMSにより検出されたGABAを示すピークについて、ピークエリアと各細胞のIC50値(50%細胞増殖抑制濃度)の関係について相関分析を行った。
(a)8種類のヒト大腸癌細胞株におけるSN-38感受性の評価
各細胞におけるIC50値は0.74±0.23~68.94±6.83nmol/Lであり、その感受性には大きな幅が認められた(図13)。
(b)GABAとSN-38感受性との相関分析
CE-TOFMSにより検出されたGABAを示すピークについて、ピークエリアと各細胞のIC50値の関係について相関分析を行ったところ、高い正の相関が認められた(図13)。
(1)方法
実施例2と同様の実験をもう一度ずつ繰り返し、それぞれ合計3回の実験から得られたデータについて、さらに詳細な解析を進めた。各細胞サンプルからCE-TOFMSにより検出されたピークについて、既にm/z及び移動時間が明らかとなっている278の標品データとの照合により、いずれかの細胞で検出が確認された146の代謝物を同定した。この146の代謝物について、8種類のヒト大腸癌細胞における細胞内量とそれぞれの細胞のLog[IC50]との関係を単回帰分析により検討した。
(a)8種類のヒト大腸癌細胞株におけるSN-38感受性の評価
8種類のヒト大腸癌細胞株(HCT-116、HT-29、HCT-15、Lovo、LS174T、SW480、SW620、WiDr)における感受性はMTS assayによって算出されるIC50を指標として評価した。その結果、WiDrのIC50(63.27±10.95nM)が最も高く、SN-38低感受性を示した。一方、LS174TのIC50(0.71±0.18nM)が最も低く、SN-38高感受性を示した(図14)。
8種類のヒト大腸癌細胞から細胞内代謝物を抽出し、CE-TOFMSにて一斉分析した。得られたデータについて、当研究室で所有する278の標品データと照合し、いずれかの細胞で検出が確認され、同定できた146の代謝物について、8種類のヒト大腸癌細胞における細胞内量とそれぞれの細胞のLog[IC50]との関係を単回帰分析により検討した。その結果、細胞内量とLog[IC50]との間に有意な関連が認められた代謝物として(p<0.01、R2≧0.7)、1-メチルアデノシン、GABA、ヒポタウリン、グルタチオン(GSH)、1-メチルニコチンアミドが得られた(図15)。これらの代謝物はいずれもSN-38高感受性細胞で細胞内レベルが低く、SN-38低感受性細胞で細胞内レベルが高かった。
Claims (22)
- 質量分析計において、本体もしくはそのフラグメントがm/z=149.05~149.06の陰イオンとして検出される分子、m/z=152.99~153.00の陰イオンとして検出される分子、m/z=724.34~724.35の陽イオンとして検出される分子、グリセロール3リン酸、ジヒドロビオプテリン、GABA、乳酸、アスパラギン、アスパラギン酸、2-メチルブチロイルカルニチン、1-メチルアデノシン、グルタチオン及びそれら分子が関与する代謝系上の物質から選ばれる1以上の分子からなる抗がん剤感受性判定マーカー。
- アスパラギン及びアスパラギン酸の比を測定するものである請求項1記載の抗がん剤感受性判定マーカー。
- グルタチオンが関与する代謝系上の物質が、グルタチオン、ヒポタウリン、1-メチルニコチンアミド、タウリン、グルタチオンジスルフィド、S-アデノシルホモシステイン、ニコチンアミド、γ-グルタミルシステイン及びスペルミンから選ばれる1以上の分子である請求項1記載の抗がん剤感受性判定マーカー。
- 抗がん剤が、植物アルカロイド系抗がん剤である請求項1~3のいずれか1項記載の抗がん剤感受性判定マーカー。
- 抗がん剤が、イリノテカン、SN-38及び/又はそれらの塩である請求項1~3のいずれか1項記載の抗がん剤感受性判定マーカー。
- 検体中の請求項1~3のいずれか1項記載の物質を測定することを特徴とする抗がん剤感受性の判定方法。
- 検体が、がんを有する被験者由来の生体試料である請求項6記載の判定方法。
- 検体が、抗がん剤を投与された、がんを有する被験者由来の生体試料である請求項6又は7記載の判定方法。
- 抗がん剤が、植物アルカロイド系抗がん剤である請求項6~8のいずれか1項記載の判定方法。
- 抗がん剤が、イリノテカン、SN-38及び/又はそれらの塩である請求項6~8のいずれか1項記載の判定方法。
- 検体中の請求項1~3のいずれか1項記載の物質を測定するためのプロトコールを含むことを特徴とする請求項6~10のいずれか1項記載の判定方法を実施するためのキット。
- 検体が、がんを有する被験者由来の生体試料である請求項11記載のキット。
- 検体が、抗がん剤を投与された、がんを有する被験者由来の生体試料である請求項11又は12記載のキット。
- 抗がん剤が、植物アルカロイド系抗がん剤である請求項11~13のいずれか1項記載のキット。
- 抗がん剤が、イリノテカン、SN-38及び/又はそれらの塩である請求項11~13のいずれか1項記載のキット。
- 請求項1~3のいずれか1項記載の物質の発現変動を指標とする抗がん剤感受性亢進剤のスクリーニング方法。
- 抗がん剤が、植物アルカロイド系抗がん剤である請求項16記載のスクリーニング方法。
- 抗がん剤が、イリノテカン、SN-38及び/又はそれらの塩である請求項16記載のスクリーニング方法。
- 請求項16~18のいずれか1項記載の方法により得られた抗がん剤感受性亢進剤。
- 請求項19記載の抗がん剤感受性亢進剤と、感受性亢進の対象となる抗がん剤とを組み合せてなるがん治療用組成物。
- 抗がん剤が、植物アルカロイド系抗がん剤である請求項20記載のがん治療用組成物。
- 抗がん剤が、イリノテカン、SN-38及び/又はそれらの塩である請求項20記載のがん治療用組成物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18190252.9A EP3438656A3 (en) | 2009-10-30 | 2010-10-29 | Anticancer agent sensitivity-determining marker |
EP10826880.6A EP2495561B1 (en) | 2009-10-30 | 2010-10-29 | Anticancer agent sensitivity-determining marker |
US13/505,175 US8809362B2 (en) | 2009-10-30 | 2010-10-29 | Anticancer agent sensitivity-determining marker |
EP16196313.7A EP3144670B1 (en) | 2009-10-30 | 2010-10-29 | Anticancer agent sensitivity-determining marker |
CN201080049509.5A CN102597762B (zh) | 2009-10-30 | 2010-10-29 | 抗癌剂感受性判定标记 |
JP2011538508A JP5548695B2 (ja) | 2009-10-30 | 2010-10-29 | 抗がん剤の感受性判定マーカー |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009250258 | 2009-10-30 | ||
JP2009-250258 | 2009-10-30 | ||
JP2010-175305 | 2010-08-04 | ||
JP2010175305 | 2010-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011052750A1 true WO2011052750A1 (ja) | 2011-05-05 |
Family
ID=43922172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/069364 WO2011052750A1 (ja) | 2009-10-30 | 2010-10-29 | 抗がん剤の感受性判定マーカー |
Country Status (5)
Country | Link |
---|---|
US (1) | US8809362B2 (ja) |
EP (3) | EP3438656A3 (ja) |
JP (1) | JP5548695B2 (ja) |
CN (2) | CN105891317B (ja) |
WO (1) | WO2011052750A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012189472A (ja) * | 2011-03-11 | 2012-10-04 | Terumo Corp | 臓器または組織の傷害検出方法 |
WO2013125675A1 (ja) * | 2012-02-23 | 2013-08-29 | 学校法人慶應義塾 | 併用抗がん剤の感受性判定マーカー |
WO2013151053A1 (ja) * | 2012-04-03 | 2013-10-10 | 国立大学法人宮崎大学 | 動脈硬化の検査方法 |
JP2016166881A (ja) * | 2011-03-24 | 2016-09-15 | 学校法人慶應義塾 | 抗がん剤感受性の判定マーカー |
WO2018181759A1 (ja) | 2017-03-31 | 2018-10-04 | 学校法人慶應義塾 | 併用抗がん剤の感受性の判定マーカー |
EP3438656A2 (en) | 2009-10-30 | 2019-02-06 | Keio University | Anticancer agent sensitivity-determining marker |
WO2019188446A1 (ja) | 2018-03-29 | 2019-10-03 | 学校法人慶應義塾 | イリノテカンを含む抗がん剤療法の感受性判定マーカー |
WO2020067228A1 (ja) | 2018-09-28 | 2020-04-02 | 学校法人慶應義塾 | 併用抗がん剤の感受性の判定マーカー |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3550306B1 (en) * | 2014-08-26 | 2021-03-03 | Keio University | Anti-cancer agent sensitivity-determining marker |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009096196A1 (ja) * | 2008-01-31 | 2009-08-06 | Keio University | 抗がん剤感受性の判定方法 |
WO2009096189A1 (ja) * | 2008-01-31 | 2009-08-06 | Keio University | 抗がん剤感受性判定マーカー |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274314B1 (en) * | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
JP4058263B2 (ja) * | 2000-11-24 | 2008-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍細胞の抗癌剤に対する感受性を検定する方法 |
JP3987953B2 (ja) * | 2001-04-20 | 2007-10-10 | サンケン電気株式会社 | ソレノイド駆動装置及び駆動方法 |
PT1583562E (pt) * | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
US20050136177A1 (en) * | 2003-08-25 | 2005-06-23 | Anthony Hesse | Method for coloring landscaping materials using foamable dry colorant |
JP2005341862A (ja) * | 2004-06-02 | 2005-12-15 | Shin Sasaki | 抗癌剤感受性予測方法、腫瘍性病変の有無の判定方法、腫瘍性病変進行度評価方法、癌治療に有効な化合物のスクリーニング方法、及び抗癌剤感受性に関連する遺伝子のスクリーニング方法 |
WO2006036476A2 (en) * | 2004-09-07 | 2006-04-06 | The General Hospital Corporation | Methods of detecting myocardial ischemia and myocardial infarction |
JP2006273760A (ja) * | 2005-03-29 | 2006-10-12 | Sony Corp | Bmal1の発現誘導を促進するRORα |
WO2008021515A2 (en) * | 2006-08-18 | 2008-02-21 | Huntington Medical Research Institutes | Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases |
CA2662655A1 (en) * | 2006-09-19 | 2008-03-27 | Metabolon, Inc. | Biomarkers for prostate cancer and methods using the same |
WO2008073878A2 (en) * | 2006-12-11 | 2008-06-19 | Board Of Regents, The University Of Texas System | Gene expression profiling of esophageal carcinomas |
EP2179292B1 (en) * | 2007-08-16 | 2012-11-28 | The Regents of the University of Michigan | Metabolomic profiling of prostate cancer |
CN101386887B (zh) * | 2008-10-31 | 2011-05-25 | 芮屈生物技术(上海)有限公司 | 一种gkn2基因的原位杂交检测试剂盒及其检测方法和应用 |
CN101548974B (zh) * | 2009-05-26 | 2010-12-01 | 上海师范大学 | 一种具有荧光和抗癌活性的化合物及其制备和应用 |
EP3438656A3 (en) | 2009-10-30 | 2019-05-01 | Keio University | Anticancer agent sensitivity-determining marker |
-
2010
- 2010-10-29 EP EP18190252.9A patent/EP3438656A3/en not_active Withdrawn
- 2010-10-29 EP EP10826880.6A patent/EP2495561B1/en active Active
- 2010-10-29 US US13/505,175 patent/US8809362B2/en active Active
- 2010-10-29 EP EP16196313.7A patent/EP3144670B1/en active Active
- 2010-10-29 CN CN201610344306.8A patent/CN105891317B/zh active Active
- 2010-10-29 CN CN201080049509.5A patent/CN102597762B/zh active Active
- 2010-10-29 WO PCT/JP2010/069364 patent/WO2011052750A1/ja active Application Filing
- 2010-10-29 JP JP2011538508A patent/JP5548695B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009096196A1 (ja) * | 2008-01-31 | 2009-08-06 | Keio University | 抗がん剤感受性の判定方法 |
WO2009096189A1 (ja) * | 2008-01-31 | 2009-08-06 | Keio University | 抗がん剤感受性判定マーカー |
Non-Patent Citations (14)
Title |
---|
CANCER RES., vol. 51, 1991, pages 4187 - 4191 |
CLIN. CANCER RES., vol. 11, 2005, pages 6901 - 6907 |
CLIN. CANCER RES., vol. 13, 2007, pages 4117 - 4122 |
INT. J. CANCER, vol. 111, 2004, pages 252 - 258 |
J. CLIN. ONCOL., vol. 11, 1993, pages 909 - 913 |
LANCET, vol. 352, 1998, pages 1407 - 1412 |
LANCET, vol. 355, 2000, pages 1041 - 1047 |
N. ENGL. J. MED., vol. 343, 2000, pages 905 - 914 |
NAT. MED., vol. 12, 2006, pages 1294 - 1300 |
PHARMACOGENET GENOMICS, vol. 17, 2007, pages 1 - 10 |
PRO. ASCO, 2005 |
See also references of EP2495561A4 * |
SEMIN. ONCOL., vol. 26, no. 1, 1999, pages 6 - 12 |
TOMOKO OHYAMA ET AL.: "Prediction of Anthracycline sensitivity by CDK profiling in combination with glutathione level", 67TH ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION, - 30 September 2008 (2008-09-30), pages 390, XP008156455 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3438656A2 (en) | 2009-10-30 | 2019-02-06 | Keio University | Anticancer agent sensitivity-determining marker |
JP2012189472A (ja) * | 2011-03-11 | 2012-10-04 | Terumo Corp | 臓器または組織の傷害検出方法 |
US10309957B2 (en) * | 2011-03-24 | 2019-06-04 | Keio University | Method for determining sensitivity to fluorouracil in a subject having colorectal cancer |
JP2016166881A (ja) * | 2011-03-24 | 2016-09-15 | 学校法人慶應義塾 | 抗がん剤感受性の判定マーカー |
JP2018054621A (ja) * | 2011-03-24 | 2018-04-05 | 学校法人慶應義塾 | 抗がん剤感受性の判定マーカー |
JP2018194556A (ja) * | 2012-02-23 | 2018-12-06 | 学校法人慶應義塾 | 併用抗がん剤の感受性判定マーカー |
WO2013125675A1 (ja) * | 2012-02-23 | 2013-08-29 | 学校法人慶應義塾 | 併用抗がん剤の感受性判定マーカー |
EP3812009A1 (en) * | 2012-02-23 | 2021-04-28 | Keio University | Combined anticancer drug sensitivity-determining marker |
US9733256B2 (en) | 2012-02-23 | 2017-08-15 | Keio University | Combined anticancer drug sensitivity-determining marker |
JP2017173334A (ja) * | 2012-02-23 | 2017-09-28 | 学校法人慶應義塾 | 併用抗がん剤の感受性判定マーカー |
JPWO2013125675A1 (ja) * | 2012-02-23 | 2015-07-30 | 学校法人慶應義塾 | 併用抗がん剤の感受性判定マーカー |
EP3326632A1 (en) * | 2012-02-23 | 2018-05-30 | Keio University | Combined anticancer drug sensitivity-determining marker |
US10481160B2 (en) | 2012-02-23 | 2019-11-19 | Keio University | Combined anticancer drug sensitivity-determining marker |
US20150038522A1 (en) * | 2012-02-23 | 2015-02-05 | Keio University | Combined anticancer drug sensitivity-determining marker |
EP2818870A4 (en) * | 2012-02-23 | 2016-02-10 | Univ Keio | COMBINED MARKER FOR DETERMINING THE SENSITIVITY TO ANTICREMENT |
WO2013151053A1 (ja) * | 2012-04-03 | 2013-10-10 | 国立大学法人宮崎大学 | 動脈硬化の検査方法 |
JPWO2013151053A1 (ja) * | 2012-04-03 | 2015-12-17 | 国立大学法人 宮崎大学 | 動脈硬化の検査方法 |
WO2018181759A1 (ja) | 2017-03-31 | 2018-10-04 | 学校法人慶應義塾 | 併用抗がん剤の感受性の判定マーカー |
US20200191772A1 (en) * | 2017-03-31 | 2020-06-18 | Keio University | Combined anticancer agent sensitivity determination marker |
WO2019188446A1 (ja) | 2018-03-29 | 2019-10-03 | 学校法人慶應義塾 | イリノテカンを含む抗がん剤療法の感受性判定マーカー |
WO2020067228A1 (ja) | 2018-09-28 | 2020-04-02 | 学校法人慶應義塾 | 併用抗がん剤の感受性の判定マーカー |
CN112770741A (zh) * | 2018-09-28 | 2021-05-07 | 学校法人庆应义塾 | 并用抗癌剂的感受性的判定标记 |
EP3858344A4 (en) * | 2018-09-28 | 2022-07-06 | Keio University | MARKER TO EVALUATE SENSITIVITY TO A COMBINATION OF ANTICANCER DRUGS |
Also Published As
Publication number | Publication date |
---|---|
EP2495561A4 (en) | 2015-12-09 |
US20120220618A1 (en) | 2012-08-30 |
EP3438656A2 (en) | 2019-02-06 |
EP3144670A3 (en) | 2017-04-26 |
EP3438656A3 (en) | 2019-05-01 |
JPWO2011052750A1 (ja) | 2013-03-21 |
EP3144670B1 (en) | 2018-10-03 |
US8809362B2 (en) | 2014-08-19 |
EP2495561A1 (en) | 2012-09-05 |
CN105891317A (zh) | 2016-08-24 |
EP2495561B1 (en) | 2016-12-14 |
EP3144670A2 (en) | 2017-03-22 |
CN102597762B (zh) | 2016-08-03 |
CN105891317B (zh) | 2019-08-09 |
CN102597762A (zh) | 2012-07-18 |
JP5548695B2 (ja) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5548695B2 (ja) | 抗がん剤の感受性判定マーカー | |
JP5461200B2 (ja) | 抗がん剤感受性判定マーカー | |
JP6527994B2 (ja) | 併用抗がん剤の感受性判定マーカー | |
US9459254B2 (en) | Method for determining sensitivity to an anticancer agent | |
EP3779451A1 (en) | Marker for determining sensitivity of irinotecan-containing anti-cancer agent therapy | |
EP3605103A1 (en) | Combined anticancer agent sensitivity determination marker | |
EP3858344A1 (en) | Marker for assessing sensitivity to combination anticancer drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080049509.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10826880 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011538508 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2010826880 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010826880 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13505175 Country of ref document: US |